- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: example GG [US9464092B2] | G1T-38 | G1T38
Compound class: Synthetic organic
Comment: Lerociclib (G1T38) is an investigational CDK4/6 inhibitor . It is being developed to help protect non-cancerous (normal) cells (in particular, hematopoietic stem and progenitor cells, and renal cells) in patients who are undergoing DNA damaging cancer chemotherapy . Lerociclib was designed to be highly selective, and short and transiently-acting.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
1. Bisi JE, Sorrentino JA, Jordan JL, Darr DD, Roberts PJ, Tavares FX, Strum JC. (2017)
Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
Oncotarget, 8 (26): 42343-42358. [PMID:28418845]
2. Stice JP, Wardell SE, Norris JD, Yllanes AP, Alley HM, Haney VO, White HS, Safi R, Winter PS, Cocce KJ et al.. (2017)
CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC.
Mol. Cancer Res., 15 (6): 660-669. [PMID:28209757]
3. Strum JC, Bisi JE, Roberts PJ, Tavares FX. (2016)
Transient protection of normal cells during chemotherapy.
Patent number: US9464092B2. Assignee: G1 Therapeutics Inc. Priority date: 15/03/2013. Publication date: 11/10/2016.